Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ABCZYOTCMKTS:CLXPFNASDAQ:PTCTNASDAQ:RYTM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABCZYAbcam$0.00$11.26▼$19.73$3.98B1.294,712 shs5,400 shsCLXPFCybin$8.10-2.9%$6.71$0.49▼$3.38$1.20BN/A551,962 shs627,029 shsPTCTPTC Therapeutics$48.89+3.4%$46.63$28.72▼$58.38$3.87B0.52860,828 shs777,100 shsRYTMRhythm Pharmaceuticals$61.88+3.8%$59.38$35.35▼$68.58$3.94B2.36555,765 shs550,380 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABCZYAbcam0.00%0.00%0.00%0.00%0.00%CLXPFCybin-2.88%+15.38%+17.90%-2.41%+2,214.95%PTCTPTC Therapeutics+3.41%+7.40%-1.27%-11.53%+39.57%RYTMRhythm Pharmaceuticals+3.84%-0.21%-5.12%+12.70%+74.75%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABCZYAbcamN/AN/AN/AN/AN/AN/AN/AN/ACLXPFCybinN/AN/AN/AN/AN/AN/AN/AN/APTCTPTC Therapeutics3.9638 of 5 stars4.31.00.04.42.90.80.0RYTMRhythm Pharmaceuticals3.9143 of 5 stars3.51.00.04.34.00.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABCZYAbcam 0.00N/AN/AN/ACLXPFCybin 0.00N/AN/AN/APTCTPTC Therapeutics 2.64Moderate Buy$63.7530.39% UpsideRYTMRhythm Pharmaceuticals 3.00Buy$76.6223.81% UpsideCurrent Analyst Ratings BreakdownLatest CLXPF, RYTM, ABCZY, and PTCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2025RYTMRhythm PharmaceuticalsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$78.00 ➝ $94.005/27/2025PTCTPTC TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$68.00 ➝ $74.005/9/2025PTCTPTC TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$55.00 ➝ $68.005/8/2025PTCTPTC TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$56.00 ➝ $42.005/7/2025PTCTPTC TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$57.00 ➝ $58.005/7/2025PTCTPTC TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$70.00 ➝ $66.005/7/2025PTCTPTC TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$113.00 ➝ $112.005/7/2025PTCTPTC TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$75.00 ➝ $67.005/7/2025PTCTPTC TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeSell ➝ Neutral$50.00 ➝ $40.005/7/2025RYTMRhythm PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$66.00 ➝ $72.004/22/2025PTCTPTC TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$65.00 ➝ $65.00(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABCZYAbcam$336.37M0.00N/AN/AN/ANaNCLXPFCybin$680K1,770.06N/AN/A$0.44 per share18.41PTCTPTC Therapeutics$1.77B2.19$2.35 per share20.80($10.85) per share-4.51RYTMRhythm Pharmaceuticals$136.86M28.77N/AN/A$2.87 per share21.56Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABCZYAbcamN/AN/A0.000.00N/AN/AN/AN/AN/ACLXPFCybin-$24.42M-$0.24N/AN/AN/AN/AN/AN/AN/APTCTPTC Therapeutics-$626.60M$6.51N/AN/AN/A-50.32%N/A-16.44%8/14/2025 (Estimated)RYTMRhythm Pharmaceuticals-$184.68M-$2.81N/AN/AN/A-230.07%-367.36%-77.47%8/5/2025 (Estimated)Latest CLXPF, RYTM, ABCZY, and PTCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025RYTMRhythm Pharmaceuticals-$0.69-$0.81-$0.12-$0.81$40.43 million$37.72 million5/6/2025Q1 2025PTCTPTC Therapeutics$0.85$10.04+$9.19N/A$437.16 million$1.18 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABCZYAbcam$0.070.36%N/AN/AN/ACLXPFCybinN/AN/AN/AN/AN/APTCTPTC TherapeuticsN/AN/AN/AN/AN/ARYTMRhythm PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABCZYAbcamN/AN/AN/ACLXPFCybinN/A13.5713.57PTCTPTC TherapeuticsN/A2.102.04RYTMRhythm PharmaceuticalsN/A3.493.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABCZYAbcamN/ACLXPFCybin0.01%PTCTPTC TherapeuticsN/ARYTMRhythm PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipABCZYAbcamN/ACLXPFCybinN/APTCTPTC Therapeutics5.50%RYTMRhythm Pharmaceuticals6.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABCZYAbcam1,750205.08 millionN/ANot OptionableCLXPFCybin50148.60 millionN/ANot OptionablePTCTPTC Therapeutics1,41079.26 million72.88 millionOptionableRYTMRhythm Pharmaceuticals14063.62 million58.02 millionOptionableCLXPF, RYTM, ABCZY, and PTCT HeadlinesRecent News About These Companies3RYTM : 12 Analysts Assess Rhythm Pharmaceuticals: What You Need To KnowMay 29 at 4:23 PM | benzinga.comRhythm Pharmaceuticals (NASDAQ:RYTM) Trading Down 4.1% - Should You Sell?May 29 at 4:16 PM | marketbeat.comFunds Go All In On Weight-Loss Leader; Stock Nears HighsMay 29 at 1:20 PM | investors.comAmeriprise Financial Inc. Purchases 11,480 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)May 29 at 3:08 AM | marketbeat.comVoloridge Investment Management LLC Purchases 27,214 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)May 25, 2025 | marketbeat.comProShare Advisors LLC Grows Stock Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)May 25, 2025 | marketbeat.comDeutsche Bank AG Has $2.73 Million Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)May 24, 2025 | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Position Trimmed by Frazier Life Sciences Management L.P.May 23, 2025 | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Given Consensus Rating of "Buy" by AnalystsMay 23, 2025 | americanbankingnews.comRafferty Asset Management LLC Sells 14,182 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)May 22, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Buys 43,904 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)May 22, 2025 | marketbeat.comOMERS ADMINISTRATION Corp Takes $425,000 Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)May 21, 2025 | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Average Rating of "Buy" from AnalystsMay 20, 2025 | marketbeat.comLazard Asset Management LLC Acquires New Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)May 18, 2025 | marketbeat.comJanus Henderson Group PLC Acquires 621,432 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)May 16, 2025 | marketbeat.comBNP Paribas Financial Markets Purchases 70,824 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)May 16, 2025 | marketbeat.comOrbimed Advisors LLC Reduces Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)May 15, 2025 | marketbeat.comRhythm FY Net Y758.00M Vs Net Y477.00MMay 14, 2025 | marketwatch.comRhythm Pharmaceuticals Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity (N=35) Treated with Setmelanotide for up to Nine Months in French Early-access ProgramMay 14, 2025 | globenewswire.comIntegral Health Asset Management LLC Invests $8.40 Million in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)May 14, 2025 | marketbeat.comNorthern Trust Corp Has $30.53 Million Stock Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)May 13, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCLXPF, RYTM, ABCZY, and PTCT Company DescriptionsAbcam OTCMKTS:ABCZYAbcam plc, a life sciences company, researches, develops, and distributes biological reagents and tools for research, drug discovery, and diagnostics in the United States, China, Japan, Germany, the United Kingdom, and internationally. The company offers various research products, including primary and secondary antibodies; ELISA and matched antibody pairs; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex assays. Its research products are used in the areas of cancer, cardiovascular, cell biology, developmental biology, epigenetics, nuclear signaling, immunology, metabolism, microbiology, neuroscience, signal transduction, and stem cells. The company also offers diagnostic and therapeutic solutions. The company also sells its products online. Abcam plc has partnership with Cancer Research UK for the development and commercialization of novel custom antibodies to support the acceleration of cancer research. Abcam plc was founded in 1998 and is headquartered in Cambridge, the United Kingdom.Cybin OTCMKTS:CLXPF$8.10 -0.24 (-2.88%) As of 05/28/2025Cybin Inc., a life sciences company, focuses on developing psychedelic therapeutics to treat various psychiatric and neurological conditions. The company operates through two segments, Serenity Life and Natures Journey. The Serenity Life segment engages in the research and development of pharmaceutical and nutraceutical psilocybin products. The Natures Journey segment focuses on non-psychedelic medical mushroom nutraceutical products. The company offers its products through various form factors, such as capsules, powders, and effervescent tablets. Cybin Inc. is headquartered in Toronto, Canada.PTC Therapeutics NASDAQ:PTCT$48.89 +1.61 (+3.41%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$48.90 +0.01 (+0.01%) As of 05/29/2025 04:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.Rhythm Pharmaceuticals NASDAQ:RYTM$61.88 +2.29 (+3.84%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$61.88 0.00 (0.00%) As of 05/29/2025 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hormel Stock Near Lows, But Tariff Relief Could Boost Outlook Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Intel's Loss Is Broadcom's Gain as AVGO Dominates Networking Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
